tbuckley/cabot-search huggingface dataset:
Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis
Authors: Yuichiro Shirai, Yuka Okazaki, Yumiko Inoue, Yuichi Tamura, Hidekata Yasuoka, Tsutomu Takeuchi, Masataka Kuwana
Journal: Arthritis & Rheumatology (2014)

To clarify the role of pentraxin 3 (PTX3), a multifunctional pattern recognition protein that can suppress fibroblast growth factor 2 (FGF-2), in systemic sclerosis (SSc)-related vasculopathy.We assessed 171 SSc patients and 19 age- and sex-matched healthy control subjects. Circulating PTX3 and FGF-2 levels were measured by enzyme immunoassay, and CD34+CD133+CD309+ endothelial progenitor cells (EPCs) were counted by flow cytometry. Correlations between PTX3 and FGF-2 and the presence or future development of vascular manifestations, including digital ulcers and pulmonary arterial hypertension (PAH), were identified by univariate and multivariate analysis. The effect of PTX3 on EPC differentiation was evaluated in proangiogenic cultures of mouse bone marrow cells in combination with colony formation assay.Circulating PTX3 and FGF-2 levels were significantly higher in SSc patients than in healthy control subjects. PTX3 was elevated in SSc patients who had digital ulcers or PAH, while FGF-2 was reduced in SSc patients with PAH. Multivariate analysis identified elevated PTX3 as an independent parameter associated with the presence of digital ulcers and PAH, and PTX3 levels were a useful predictor of future occurrences of digital ulcers. Reduced FGF-2 was independently associated with the presence of PAH. EPC counts were significantly lower in patients with digital ulcers or PAH and correlated negatively with circulating PTX3 concentrations. Finally, PTX3 inhibited EPC differentiation in vitro.In SSc patients, exposure to high concentrations of PTX3 may suppress EPC-mediated vasculogenesis and promote vascular manifestations such as digital ulcers and PAH.
Carriage of group B Streptococcus in pregnant women and newborns: a 2-year study at Perugia General Hospital
Authors: Alessandra Sensini, Luciana Tissi, Nadia Verducci, Maristella Orofino, Christina von Hunolstein, Bruno Brunelli, Gian Luca Malà, Fausto Perocchi, Roberta Brunelli, Vincenzo Lauro, Remo Ferrarese, Giovanni Gilardi
Journal: Clinical Microbiology and Infection (1997)
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Authors: J K Weick, J Crowley, R B Natale, B L Hom, S Rivkin, C A Coltman, S A Taylor, R B Livingston
Journal: Journal of Clinical Oncology (1991)

Six hundred eighty assessable patients with measureable stage III M1, non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms including cisplatin, etoposide (VP-16) +/- methylglyoxal bisguanylhydrazone (MGBG; PVp, PVpM); cisplatin, vinblastine (PVe); or PVe alternating with vinblastine, mitomycin (PVeMi); or fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP). The overall response rate was 20% with 3% complete responses and 17% partial remissions. The duration of these responses was not statistically different by treatment regimen and varied from 2.7 months to 5.0 months. The overall median survival for all patients was 5.3 months and is not different by treatment. Toxicity was greater in PVpM. The similarity of results for response, duration of response, and survival does not establish the superiority of any of these platinum-based regimens for standard clinical usage.
The role of video-assisted thoracic surgery on the diagnostic evaluation and the therapeutic management of thoracic injuries
Authors: Petros Michos, Athanassios Stamatelopoulos, Ioannis Gakidis, Christos Chatziantoniou, Trasyvoulos Michos, Ilias Voutas, Dimitra Peristeri, Nikolaos Manolis
Journal: European Respiratory Journal (2012)

AIM: The aim of this study was to evaluate the experience of our department with the use of video-assisted thoracic surgery (VATS) in chest trauma.  MATERIALS - METHODS : Between January 1999 and December 2013, 88,244 patients presented with chest trauma to the emergency room, and 8064 were admitted to our department. Sixty five hemodynamically stable patients (0,8%) underwent VATS. They were 54 men and 11 women with an average age of 42 years (range, 19–67 years).  RESULTS : Indications included post-traumatic hemothorax in 31 patients, and post-traumatic empyema in 9, treated after 24 h of trauma. Indications for exploratory VATS in the acute phase(‹ 24h) included suspected diaphragmatic injury in 6 patients, persistent huge pneumothorax in 6, continued hemorrhage in 8 and removal of intrathoracic foreign body in 5. There was no mortality and complications occurred in 9 patients (13,7%).  CONCLUSIONS: Management of thoracic injuries by using VATS in hemodynamically stable patients provides diagnostic accuracy and therapeutic efficacy. It can be successfully applied in the trauma setting and thoracic surgeons should gain experience with its use.
Chemotherapy of invasive thymoma.
Authors: A Fornasiero, O Daniele, C Ghiotto, F Sartori, F Rea, M Piazza, L Fiore-Donati, P Morandi, S M Aversa, A Paccagnella
Journal: Journal of Clinical Oncology (1990)

Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988. All patients received the following chemotherapy in 4-day courses: 50 mg/m2 of cisplatin intravenously (IV) and 40 mg/m2 of doxorubicin IV on day 1; 0.6 mg/m2 of vincristine IV on day 3; and 700 mg/m2 of cyclophosphamide IV on day 4 (ADOC). The courses were repeated every 3 weeks, and toxic effects were tolerable. The radiologically defined overall clinical response rate (complete plus partial response) was 91% with 47% clinical complete remissions; median time to progression was 11 months (range, 0 to 96) and the median estimated (Kaplan-Meier) progression-free interval was 22 months. Five of the 15 clinical complete remissions were pathologically confirmed at thoracotomy. We believe the ADOC regimen qualifies for adjuvant and preoperative treatment of invasive thymoma due to the high complete response and overall response rates.
The Significance of Glycolysis&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Samuel Graff, Hermann Moser, Olga Kastner, Ada M. Graff, Myron Tannenbaum
Journal: JNCI Journal of the National Cancer Institute (1965)

L929 mouse fibroblasts and Ehrlich ascites cells grew well in media containing very low levels of glucose. The generation rates of the cultures were independent of glucose concentration and glucose consumption. At low levels of glucose, 5 mg per 100 ml or less, both lines of cells consumed rather than produced lactate. The administration of relatively high levels of glucose to these cells sharply inhibited deoxyribonucleic acid and ribonucleic acid synthesis and generation rates. It is concluded that aerobic glycolysis is a general and transitory defense against high glucose influx. This defense mechanism manifests itself in vitro because the requisite hormones limiting the flux of glucose across cell membranes are either absent or nonoperative. It is surmised that aerobic glycolysis is exhibited in vivo only by those cells refractory to glucose flux regulation—cancer cells.
Will a Partial Posterior Annuloplasty Ring Prevent Acute Ischemic Mitral Regurgitation?
Authors: Tomasz A. Timek, Paul Dagum, David T. Lai, Frederick Tibayan, David Liang, George T. Daughters, Motoya Hayase, Neil B. Ingels, D. Craig Miller
Journal: Circulation (2002)

Background Acute posterolateral ischemia in sheep results in ischemic mitral regurgitation (IMR). While complete ring annuloplasty prevents acute IMR, partial annuloplasty rings may offer a more physiologic repair, but are untested in animal models of IMR. Methods Radiopaque markers were placed on the LV, mitral annulus (MA), and leaflets in 13 sheep. Seven sheep served as controls, and 6 had a St. Jude Tailor partial flexible ring implanted (29 mm in 5, 31 mm in 1). After 8±1 day, the animals were studied with biplane videofluoroscopy and echocardiography before and during acute posterolateral LV ischemia (balloon occlusion of circumflex artery). Mitral annular area (MAA), septal-lateral annular diameter (SL), annular perimeters, and leaflet edge separation were calculated from 3-D marker coordinates. Results The average degree of mitral regurgitation increased from 0.0±0.0 to 2.1±0.7 ( P =0.0006) in the control group during acute ischemia but remained unchanged in the Tailor group (0.1±0.2 for both conditions). The change in MAA throughout the cardiac cycle before ischemia was 17±4% in control animals, but only 5±2% ( P =0.0002) in the Tailor ring group. Unlike the control animals, there was no increase in MAA (5.4±0.8 and 5.5±0.7 cm 2 , respectively; p=NS) nor dilatation of the muscular annulus (6.2±0.3 and 6.2±0.4, respectively; p=NS) during ischemia with the Tailor ring. Mitral SL dimension increased slightly with ischemia (2.3±0.2 versus 2.2±0.2 cm, P =0.03). Although posterior leaflet motion was limited, as observed with complete rings, normal annular flexion was maintained with the Tailor ring before and during acute ischemia. Conclusions The Tailor partial annuloplasty ring prevented acute IMR probably by limiting SL diameter dilatation during acute ischemia. In this animal model of acute IMR, a partial, flexible posterior annuloplasty ring is as effective as a complete ring.
Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy
Authors: Marieta M. Ruseva, Tao Peng, Melissa A. Lasaro, Keith Bouchard, Susan Liu-Chen, Fang Sun, Zhao-Xue Yu, Andre Marozsan, Yi Wang, Matthew C. Pickering
Journal: Journal of the American Society of Nephrology (2015)

C3 glomerulopathy refers to renal disorders characterized by abnormal accumulation of C3 within the kidney, commonly along the glomerular basement membrane (GBM). C3 glomerulopathy is associated with complement alternative pathway dysregulation, which includes functional defects in complement regulator factor H (FH). There is no effective treatment for C3 glomerulopathy. We investigated the efficacy of a recombinant mouse protein composed of domains from complement receptor 2 (CR2) and FH (CR2-FH) in two models of C3 glomerulopathy with either preexisting or triggered C3 deposition along the GBM. FH-deficient mice spontaneously develop renal pathology associated with abnormal C3 accumulation along the GBM and secondary plasma C3 deficiency. CR2-FH partially restored plasma C3 levels in FH-deficient mice 2 hours after intravenous injection. CR2-FH specifically targeted glomerular C3 deposits, reduced the linear C3 reactivity assessed with anti-C3 and anti-C3b/iC3b/C3c antibodies, and prevented further spontaneous accumulation of C3 fragments along the GBM. Reduction in glomerular C3d and C9/C5b-9 reactivity was observed after daily administration of CR2-FH for 1 week. In a second mouse model with combined deficiency of FH and complement factor I, CR2-FH prevented de novo C3 deposition along the GBM. These data show that CR2-FH protects the GBM from both spontaneous and triggered C3 deposition in vivo and indicate that this approach should be tested in C3 glomerulopathy.
Unusual forms of pulmonary tuberculosis
Authors: Nahid Zaghba, Najiba Yassine, Ahlam Ech-Cherrate, Abdelaziz Bakhatar, Abdelkrim Bahlaoui
Journal: European Respiratory Journal (2011)

Pulmonary tuberculosis PT is generally easily recognized by its classic features. Nevertheless, the radiological setting could be misleading, suggesting other diagnoses. We report 51 cases of PT with unusual in appearance and site (pseudotumoral 14 cases, endobronchial 25 cases, basal 8 cases and balloon release 4 cases). It occurred in 30 males and 21 females with a mean age of 40 years old (range age 15-71 years old). Twenty males were smokers. The clinical setting was dominated by bronchial syndrome, chest pain and haemoptysis. Chest X-ray showed pulmonary opacities-like tumor in 14 cases, retractable opacities in 20 cases, enlarged mediastinal lymph node in 5 cases, basal excavated opacities in 10 cases and a balloon release in 4 cases. Bronchoscopy showed endobronchial granulomas in 15 cases, bud-like tumor in 8 cases and mediastinal lymph node fistula in a bronchus in 2 cases. Chest scan highlighted a peripheral tumor-like process in 6 cases and a balloon release in 4 cases. The diagnosis of PT was confirmed by bacilloscopy in bronchial aspirate in 26 cases, bronchial biopsy in 20 cases, transmural biopsy in 6 cases, biopsy under thoracoscopy in 4 cases and an open surgical biopsy in 3 cases. Under antibacillary therapy, the evolution was favorable in all the cases. Despite their rarity, unusual forms of tuberculosis should be better known as it could simulate cancer especially in its particular pseudotumoral form.
Characterization of Acinetobacter baumannii carrying blaOXA.23blaPER-1 and armA in a Korean hospital
Authors: J.W. Kim, S.T. Heo, J.S. Jin, C.H. Choi, Y.C. Lee, Y.G. Jeong, S.-J. Kim, J.C. Lee
Journal: Clinical Microbiology and Infection (2008)
Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients
Authors: C.-H. Lai, W.-W. Wong, C. Chin, C.-K. Huang, H.-H. Lin, W.-F. Chen, K.-W. Yu, C.-Y. Liu
Journal: Clinical Microbiology and Infection (2006)
Oncornavirus Lytic Activity in the Serum of Gibbon Apes
Authors: R. E. Gallagher, A. W. Schrecker, C. A. Walter, R. C. Gallo
Journal: JNCI Journal of the National Cancer Institute (1978)

Fresh blood serum from normal gibbon apes (Hylobates lar) contained heat-sensitive lytic activity for various mammalian oncornaviruses. Lytic activity quantitatively similar to that in gibbon serum was demonstrated in serum from three other primate species, including man; it was demonstrated to be low or absent in lower mammalian species with the exception of domestic cats, which had intermediate levels of serum lytic activity. Gibbons that acquired infectious gibbon ape leukemia virus, either naturally by exposure to a virus-shedding ape or experimentally by deliberate virus inoculation, had the same levels of serum lytic activity as did unexposed gibbons that had no detectable antibodies to gibbon ape leukemia virus. A leukemic-viremic gibbon had low or absent serum oncornavirus lytic activity. These results indicated that serum lytic activity does not necessarily protect against infection by oncornaviruses, although it may limit virus replication and/or dissemination.
Origin of Testicular Teratomas From Primordial Germ Cells in Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Leroy C. Stevens
Journal: JNCI Journal of the National Cancer Institute (1967)

Journal Article Origin of Testicular Teratomas From Primordial Germ Cells in Mice Get access Leroy C. Stevens Leroy C. Stevens The Jackson Laboratory, Bar Harbor, Maine 04609 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 38, Issue 4, April 1967, Pages 549–552, https://doi.org/10.1093/jnci/38.4.549 Published: 01 April 1967 Article history Received: 02 September 1966 Published: 01 April 1967
A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms.
Authors: J C Holland, G R Morrow, A Schmale, L Derogatis, M Stefanek, S Berenson, P J Carpenter, W Breitbart, M Feldstein
Journal: Journal of Clinical Oncology (1991)

A randomized nonblinded study was performed in three cancer centers to test over a 10-day period the efficacy of (1) a triazolobenzodiazepine, alprazolam, 0.5 mg three times a day and (2) use of a behavioral technique in which patients were trained in progressive muscle relaxation at an initial session with a behavioral psychologist and then asked to listen at home to an audiotape of the session three times a day. Of 147 cancer patients who met entry levels of distress and completed the study, uncontrolled for site or disease stage, 70 were randomized to drug, 77 to relaxation. Four measures of anxiety and depression were used: Covi, Raskin, Affects Balance, and Symptoms Checklist-90 (SCL-90). Results showed that both treatment arms resulted in significant (P less than .001) decrease in observer and patient-reported anxious and depressed mood symptoms. Although both treatment arms were effective, patients receiving the drug showed a slightly more rapid decrease in anxiety and greater reduction of depressive symptoms. These findings confirm efficacy of both alprazolam and relaxation to reduce cancer-related anxiety and depression. As safe, inexpensive, and effective interventions, physicians should consider their use in cancer patients experiencing anxiety and depressive symptoms.
Suppressor Factor Secreted by T-Lymphocytes From Tumor-Bearing Mice 2
Authors: Abraham J. Treves, Irun R. Cohen, Michael Feldman
Journal: JNCI Journal of the National Cancer Institute (1976)

Spleen cells from C57BL mice bearing the syngeneic carcinoma 3LL enhanced tumor growth. Tumor growth was also enhanced by a soluble factor found in the media of cultured spleen cells from tumor-bearing animals. This factor suppressed a protective immune response of the host and was found to be a product of T-lymphocytes. Removal of B-lymphocytes and macrophages did not prevent its appearance in the culture media, whereas removal of T-lymphocytes inhibited its appearance. Similar suppressor factors were obtained from C3H mice bearing the 3LL tumor and from mice with other tumors. The suppressing factor produced after the growth of 3LL tumor also enhanced the growth of other tumors. It could act on strains incompatible with the donor of the factor-producing cells. Hence tumor growth was possibly facilitated by soluble products of T-lymphocytes that were found in spleens of tumor-bearing mice and that nonspecifically suppressed immune defense mechanisms.
Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy
Authors: S. Selleri, F. Arnaboldi, M. Palazzo, U. Hussein, A. Balsari, C. Rumio
Journal: British Journal of Dermatology (2005)

Journal Article Caveolin‐1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy Get access S. Selleri, S. Selleri Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar F. Arnaboldi, F. Arnaboldi Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar M. Palazzo, M. Palazzo Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar U. Hussein, U. Hussein Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar A. Balsari, A. Balsari Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar C. Rumio C. Rumio Department of Human Morphology and Institute of Pathology, National Cancer Institute, Università degli Studi di Milano, Via Mangiagalli, 31, 20133 Milan, Italy Cristiano Rumio. E‐mail: cristiano.rumio@unimi.it Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 153, Issue 3, 1 September 2005, Pages 506–513, https://doi.org/10.1111/j.1365-2133.2005.06746.x Published: 01 September 2005 Article history Accepted: 28 February 2005 Published: 01 September 2005
Peak cough flow via tracheostomy - A useful assessment tool before decannulation?
Authors: Claire Fitzgerald, Eleanor Main, Craig Brown
Journal: European Respiratory Journal (2013)

Background:   The decision to remove a tracheostomy tube (TT) balances the risk of premature decannulation and the benefit of minimising cannulation time. Objective criteria guiding this decision are lacking. A critical peak cough flow (PCF) of 160 L/min following TT removal is considered highly predictive of decannulation outcome.    Aims:   To ascertain the relationship of PCF measured via TT (PCF1) to PCF measured via oronasal mask following decannulation (PCF2), and determine a predictive model for PCF2>160 based on PCF1 and other potentially influential variables.    Methods:   A retrospective case note review was undertaken of tracheostomy care proformas completed in a hospital where PCF was measured pre- and post-decannulation. Twenty-three case notes were identified for inclusion.    Results:  PCF1 and PCF2 had a fair positive relationship (r s =0.42, p p =0.002), although PCF2–PCF1 difference varied highly (range -146.4–243.0 L/min). PCF1 alone or in combination with other variables was not predictive of PCF2>160. For 8 patients with PCF2    Conclusions:   In the small heterogeneous study population, PCF1 was not a useful assessment tool to predict a PCF2>160 L/min. The significant PCF1-PCF2 relationship and diminished specificity of the PCF
Clinical staging underestimates pathological stage in non-small cell lung cancer
Authors: L Camporota
Journal: Thorax (2005)

▴ Lopez-Encuentra A, Garcia-Lujan R, Rivas JJ, et al . Comparison between clinical and pathologic staging in 2,994 cases of lung cancer. Ann Thorac Surg2005;79:974–9

[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4]



Clinical staging of lung cancer should establish a cTNM reliably predictive of the pathological stage. This study analysed 2994 lung cancers, operated on with curative intent in Spain between 1993 and 1997, with the aim of determining the agreement between clinical and pathological staging.

93% of patients were …

 [1]: {openurl}?query=rft.jtitle%253DThe%2BAnnals%2Bof%2BThoracic%2BSurgery%26rft.stitle%253DAnn.%2BThorac.%2BSurg.%26rft.issn%253D0003-4975%26rft.aulast%253DLopez-Encuentra%26rft.auinit1%253DA.%26rft.volume%253D79%26rft.issue%253D3%26rft.spage%253D974%26rft.epage%253D979%26rft.atitle%253DComparison%2BBetween%2BClinical%2Band%2BPathologic%2BStaging%2Bin%2B2%252C994%2BCases%2Bof%2BLung%2BCancer%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.athoracsur.2004.06.004%26rft_id%253Dinfo%253Apmid%252F15734416%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx
 [2]: /lookup/external-ref?access_num=10.1016/j.athoracsur.2004.06.004&link_type=DOI
 [3]: /lookup/external-ref?access_num=15734416&link_type=MED&atom=%2Fthoraxjnl%2F60%2F7%2F581.atom
 [4]: /lookup/external-ref?access_num=000227414400034&link_type=ISI